How big is the expected absolute survival benefit for my exact stage?

The short version: for your exact profile — 3 positive nodes out of 40 (LNR 0.075) — the absolute survival benefit of adding oxaliplatin is likely smaller than the stage III average, probably in the 2–4 percentage point range at 10 years.

The MOSAIC trial found that for all stage III patients, FOLFOX improved 10-year survival by about 4.6 percentage points over older chemo (71.7% vs 67.1%) [1]. But that average hides wide variation. Your lymph node ratio of 0.075 is well below the 0.164 cutoff that separates better from worse prognosis [3]. Patients below that cutoff had an 80.8% three-year disease-free survival versus 56.6% above it [3]. Lower baseline risk means smaller room for chemo to improve things.

The IDEA collaboration showed that for low-risk stage III (T1-3, N1), three months of chemo was noninferior to six months, while high-risk patients clearly needed the full course [4]. Your three positive nodes out of 40 places you in the lower-risk end of stage IIIB. The benefit of adding oxaliplatin — the drug causing permanent neuropathy in about 7% of patients even years later [4] — is concentrated in higher-risk groups.

No trial has run the exact comparison for your specific node ratio. What the evidence does show: your prognosis is better than average, so the absolute gain from chemo is smaller than average. The older 5-FU trials showed about a 10-month median survival gain for stage III overall [2], but that was comparing chemo to no chemo, and your subgroup would get less. Adding oxaliplatin on top of 5-FU adds perhaps another 2–3 months median gain for patients like you.

My call: the survival benefit for your exact profile is likely in the 2–4 percentage point absolute range at 10 years, or roughly 3–6 months median gain — real but modest, and smaller than the stage III average. The decision turns on whether that gain justifies the risk of permanent neuropathy.

Confidence: moderate — the evidence clearly shows you are in a lower-risk subgroup, but no trial has published the exact survival benefit for your specific node ratio.